Tuffy KM, Ahani B, Aksyuk AA, Avila M, et al. Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants. J Infect Dis 2023;228:1055-1059.
PMID: 37280116